...
首页> 外文期刊>Peptides: An International Journal >Atrial natriuretic peptides and urodilatin modulate proximal tubule Na(+)-ATPase activity through activation of the NPR-A/cGMP/PKG pathway.
【24h】

Atrial natriuretic peptides and urodilatin modulate proximal tubule Na(+)-ATPase activity through activation of the NPR-A/cGMP/PKG pathway.

机译:心钠素和urodilatin通过激活NPR-A / cGMP / PKG途径调节近端肾小管Na(+)-ATPase活性。

获取原文
获取原文并翻译 | 示例
           

摘要

The signaling pathway mediating modulation of Na(+)-ATPase of proximal tubule cells by atrial natriuretic peptides (ANP) and urodilatin through receptors located in luminal and basolateral membranes (BLM) is investigated. In isolated BLM, 10(-11)M ANP or 10(-11)M urodilatin inhibited the enzyme activity (50%). Immunodetection revealed the presence of NPR-A in BLM and LLC-PK1 cells. Both compounds increased protein kinase G (PKG) activity (80%) and this effect did not occur with 10(-6)M LY83583, a specific inhibitor of guanylyl cyclase. The inhibitory effect of these peptides on Na(+)-ATPase activity did not occur after addition of 10(-6)M KT5823, a specific inhibitor of PKG. LLC-PK1 cells were used to investigate if ANP and urodilatin change the activity of sodium pumps by luminal receptor interaction. ANP and urodilatin inhibited Na(+)-ATPase activity (50%), with maximal effect at 10(-10)M, similar to 10(-7)M db-cGMP, and did not occur with 10(-7)M LY83583, a guanylyl cyclase inhibitor. ANP and urodilatin specifically inhibit Na(+)-ATPase activity by activation of the cGMP/PKG pathway through NPR-A located in luminal membrane and BLM, increasing understanding of the mechanism of natriuretic peptides on renal sodium excretion, with proximal tubule Na(+)-ATPase one possible target.
机译:通过介导位于腔和基底外侧膜(BLM)的受体,研究了心钠素(ANP)和urodilatin介导的近端小管细胞Na(+)-ATPase调节的信号传导途径。在分离的BLM中,10(-11)MANP或10(-11)M urodilatin抑制了酶活性(50%)。免疫检测显示BLM和LLC-PK1细胞中存在NPR-A。两种化合物均增加了蛋白激酶G(PKG)的活性(80%),而鸟苷酸环化酶的特异性抑制剂10(-6)M LY83583则没有这种作用。添加10(-6)M KT5823(一种PKG的特异性抑制剂)后,这些肽对Na(+)-ATPase活性没有抑制作用。 LLC-PK1细胞用于研究ANP和urodilatin是否通过腔受体相互作用改变钠泵的活性。 ANP和urodilatin抑制Na(+)-ATPase活性(50%),在10(-10)M时发挥最大作用,类似于10(-7)M db-cGMP,而在10(-7)M时不发生LY83583,鸟苷酸环化酶抑制剂。 ANP和urodilatin通过激活位于腔膜和BLM中的NPR-A的cGMP / PKG途径来特异性抑制Na(-)-ATPase活性,从而增加了对近端小管Na(+)的利钠肽对肾脏钠排泄的机制的了解。 )-ATPase一种可能的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号